Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 9/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24212340 | 0.87 | PDK1 (0.47) | PDK1RAB9AGAATSHRPDK2 | |
| SCHEMBL3596109 | 0.84 | TSHR (0.54) | TSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL3632433 | 0.82 | PDK1 (0.54) | PDK1RAB9AGAATSHRPDK2 | |
| SCHEMBL3056327 | 0.81 | PDK1 (0.55) | PDK1RAB9AGAATSHRPDK2 | |
| SCHEMBL3061506 | 0.80 | RAB9A (0.55) | PDK1RAB9AGAATSHRPDK2 | |
| SCHEMBL5482146 | 0.78 | KMT2A (0.67) | PDK1RAB9AGAATSHRPDK2 | |
| SCHEMBL3065409 | 0.78 | GAA (0.63) | PDK1RAB9AGAATSHRPDK2 | |
| SCHEMBL28072931 | 0.76 | GAA (0.53) | PDK1RAB9AGAATSHRNPC1 | |
| SCHEMBL3058847 | 0.76 | PDK1 (0.50) | PDK1RAB9AGAATSHRPDK2 | |
| SCHEMBL3049960 | 0.75 | PDK1 (0.52) | PDK1RAB9AGAATSHRPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048579-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISTS | ARISTA LUCA | 2010-02-25 | — | — | US | claimed |
| US-20100048579-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISTS | ARISTA LUCA | 2010-02-25 | — | — | US | disclosed |
| EP-2146970-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISIS | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008125627-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISIS | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048579-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISTS | GPBAR1, GPER1, ADRB1 | PDK1 1075/4885RAB9A 2718/4885GAA 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.